Aveo Group

AVEO Oncology, an LG Chem company, is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for cancer. The company's flagship product, FOTIVDA (tivozanib), is an oral, next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor approved for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). AVEO's pipeline includes several clinical-stage candidates, such as ficlatuzumab, a monoclonal antibody targeting the HGF/c-Met pathway, and AV-380, a potent humanized inhibitory antibody targeting GDF15 for the treatment of cancer cachexia. The company utilizes its proprietary Human Response Platform to identify and develop therapies that address unmet needs in oncology. Following its acquisition by LG Chem in 2023, AVEO serves as the global hub for the parent company's oncology business.